Kaken Pharmaceutical Co. Ltd (KKPCF) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Kaken Pharmaceutical Co. Ltd stock $7.86, price $23.97, that is 67.2% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kaken Pharmaceutical Co. Ltd
KKPCF · USFar too expensive (fair value 67% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $18.05 – $29.50 · fair‑value band $5.89 – $9.82 · the $23.97 price screens above the $7.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Kaken Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.
Show moreShow less
The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions.
It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle.
In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia.
Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan.
Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Stock analysis
Kaken Pharmaceutical Co. Ltd (KKPCF) currently trades at $23.97, while our model-based Fair Value estimate is $7.86, 67% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of $16.02 per share, and 1 of the 10 models we run sit above the $23.97 price.
Bear case: the Earnings-Based group reads lowest at $2.97, and 9 of the 10 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $5.89 (bear) to $9.82 (bull), the price of $23.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Kaken Pharmaceutical Co. Ltd reported revenue of ¥77.4B in FY2026 versus ¥76.0B in FY2022, a compound +0.4%/yr. Reported net income was ¥2.2B in FY2026, compounding −31.1%/yr from FY2022.
Key figures
Market cap $985M Small · EPS (TTM) $−0.7000 · Dividend yield 5.0% · Net margin 2.8% · Return on equity 6.9% · Return on assets (EBIT) 6.2% (5-year average) · Operating margin 36.2% · Revenue (TTM) ¥88.2B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −67%, KKPCF screens richer than that median.
Fair Value models
All 10 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
KKPCF screens overvalued: fair value 67% below the price. Compare with Merck KGaA →
Compare Kaken Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs KKPCF |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs KKPCF |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs KKPCF |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs KKPCF |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs KKPCF |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs KKPCF |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs KKPCF |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs KKPCF |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs KKPCF |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs KKPCF |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kaken Pharmaceutical Co. Ltd (KKPCF) overvalued or undervalued?
What is the fair value of KKPCF?
What is the quality score of KKPCF?
What is the price target for Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the Kaken Pharmaceutical Co. Ltd stock forecast for 2026?
What is the revenue of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Does Kaken Pharmaceutical Co. Ltd pay a dividend?
How much is the dividend of Kaken Pharmaceutical Co. Ltd (KKPCF) and when is the ex-dividend date?
What is the intrinsic value of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Is Kaken Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KKPCF?
How much is Kaken Pharmaceutical Co. Ltd worth?
What do the bullish and bearish scenarios say about KKPCF?
How solid is the balance sheet of Kaken Pharmaceutical Co. Ltd (KKPCF)?
How far is KKPCF from its 52-week high?
Which stocks are comparable to Kaken Pharmaceutical Co. Ltd?
Is Kaken Pharmaceutical Co. Ltd stock attractive at the current price?
How is the fair value of KKPCF calculated?
Is it still worth investing in stocks now?
What is the share price of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What should I pay attention to with Kaken Pharmaceutical Co. Ltd right now?
Where does the earnings growth of Kaken Pharmaceutical Co. Ltd (KKPCF) come from?
Key figures of Kaken Pharmaceutical Co. Ltd
How large is the market capitalisation of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What are the earnings per share of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the dividend yield of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the net margin of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the return on equity of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the EBIT return on assets of Kaken Pharmaceutical Co. Ltd (KKPCF)?
What is the operating margin of Kaken Pharmaceutical Co. Ltd (KKPCF)?
How fast is revenue growing at Kaken Pharmaceutical Co. Ltd (KKPCF)?
How fast are earnings growing at Kaken Pharmaceutical Co. Ltd (KKPCF)?
How much free cash flow does Kaken Pharmaceutical Co. Ltd (KKPCF) generate?
How much net cash does Kaken Pharmaceutical Co. Ltd (KKPCF) hold?
Watch Kaken Pharmaceutical Co. Ltd in the live analysis
One click puts Kaken Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.